

WE CARE ABOUT FOOTBALL



# **UEFA Anti-Doping Regulations**

**Edition 2006**



### **Anti-Doping Panel 2006/07**

Chairman:	Dr Jacques Liénard, Chief Medical Officer, French Football Federation (France)
Members:	Dr Ian Beasley, Club Team Doctor (England) Dr Mogens Kreutzfeldt, Judge, Danish Sports Council (Denmark) Mr Hakan Nyberg, Anti-Doping Programme Manager, Swedish Sports Confederation (Sweden) Dr Martial Saugy, Director, of the Anti- Doping Laboratory, Lausanne (Switzerland) Mr Philippe Verbiest, lawyer, International Cycling Federation (Belgium) Prof. Jean-Luc Veuthey, Head of Drug and Pharmaceutical Analysis, University of Geneva (Switzerland)

### **Medical Committee 2005/06**

Chairman:	Dr Urs Vogel (Switzerland)
Vice-Chairmen:	Prof. Jan Ekstrand (Sweden) Prof. W. Stewart Hillis (Scotland)
Members:	Prof. Mehmet Binnet (Turkey) Prof. Wilfried Kindermann (Germany) Dr Mogens Kreutzfeldt (Denmark) Dr Jacques Liénard (France) Dr Pedro Correia Magro (Portugal) Dr Alfonso Moreno Gonzalez (Spain) Dr Alan Hodson (England) Prof. Paolo Zeppilli (Italy)
FIFA representative:	Dr Michel D'Hooghe (Belgium) Chairman, FIFA Sports Medical Committee

## **Doping Control Officers Panel**

### **Members:**

Prof. Mehmet Binnet (Turkey)  
Dr José Antonio Casajus (Spain)  
Dr Marcos Del Cuadro (Switzerland)  
Dr José Fernando De Magalhães  
Marques (France)  
Dr Marc Dobbeleir (Belgium)  
Dr Domingos Dias Gomes (France)  
Dr Matteo Framaglia (Italy)  
Dr George Frank (Israel)  
Dr Eleonora Gambillara (Switzerland)  
Dr Helle Handler Petersen (Denmark)  
Dr Frits Kessel (Netherlands)  
Dr Jens Kleinfeld (Germany)  
Dr Franz Krosshuber (Austria)  
Dr Jacques Liénard (France)  
Dr Pavel Malovic (Slovakia)  
Dr Vlastibor Minarovjech jr. (Slovakia)  
Dr Katrin Riechert (Germany)  
Dr Hans Scholtz (Netherlands)  
Dr Michael Sjöo (Sweden)  
Dr Ilija Stoilov (FYR Macedonia)  
Dr Ton Verhagen (Netherlands)  
Dr Urs Vogel (Switzerland)  
Dr Michael Zager (Israel)  
Dr Nikolaos Zamboglou (Cyprus)

***Other Doping Control Officers may be appointed as necessary.***

## CONTENTS

<b>I</b>	<b>Definition</b>	<b>1</b>
	<b>Article 1</b>	<b>1</b>
	DEFINITION OF DOPING	1
	<b>Article 2</b>	<b>1</b>
	ANTI-DOPING RULE VIOLATIONS	1
	<b>Article 3</b>	<b>2</b>
	PROOF OF DOPING	2
	BURDENS AND STANDARDS OF PROOF	2
	METHODS OF ESTABLISHING FACTS AND PRESUMPTIONS	2
	<b>Article 4</b>	<b>3</b>
	PROHIBITED SUBSTANCES AND METHODS	3
	THERAPEUTIC USE EXEMPTION (TUE)	3
<b>II</b>	<b>Doping Control Organisation</b>	<b>4</b>
	<b>Article 5</b>	<b>4</b>
	ORGANISATION	4
	<b>Article 6</b>	<b>5</b>
	OBLIGATIONS OF NATIONAL ASSOCIATIONS, CLUBS AND PLAYERS	5
	<b>Article 7</b>	<b>5</b>
	DRAW PROCEDURE FOR IN-COMPETITION CONTROLS	5
	<b>Article 8</b>	<b>7</b>
	DRAW PROCEDURE FOR OUT-OF-COMPETITION CONTROLS	7
	<b>Article 9</b>	<b>8</b>
	SUSPICION OF DOPING	8
	<b>Article 10</b>	<b>9</b>
	DOPING CONTROL STATION	9
	<b>Article 11</b>	<b>9</b>
	DOPING CONTROL PROCEDURE FOR URINE SAMPLES	9
	PROCEDURE IF THE STIPULATED URINE VOLUME OF 75 ML IS NOT OBTAINED	10
	PROPERTY OF SAMPLES	11
	<b>Article 12</b>	<b>11</b>
	ANALYSIS OF SAMPLES	11
	<b>Article 13</b>	<b>11</b>
	PROCEDURE IF SAMPLE A PRODUCES AN ADVERSE ANALYTICAL FINDING	11
	<b>Article 14</b>	<b>12</b>
	RIGHT TO REQUEST AN ANALYSIS OF SAMPLE B	12
	<b>Article 15</b>	<b>13</b>
	PROCEDURE IF SAMPLE B CONFIRMS THE A SAMPLE	13
	<b>Article 16</b>	<b>13</b>
	DOPING CONTROL PROCEDURE FOR BLOOD SAMPLES	13
	PROPERTY OF SAMPLES	14
	<b>Article 17</b>	<b>15</b>
	DISCIPLINARY PROCEDURE IN THE EVENT OF ANTI-DOPING RULE VIOLATIONS	15

<b>III</b>	<b>Further provisions</b>	<b>15</b>
	<b>Article 18</b>	<b>15</b>
	COURT OF ARBITRATION FOR SPORT	15
	<b>Article 19</b>	<b>15</b>
	CLOSING PROVISIONS	15
APPENDIX A:	INSTRUCTIONS TO ORGANISERS OF UEFA MATCHES	17
APPENDIX B:	PLAN OF DOPING CONTROL STATION	19
APPENDIX C:	LIST OF WADA-ACCREDITED LABORATORIES IN EUROPE	20
APPENDIX D:	FORMS	25
	DOPING CONTROL DRAW FORM (D1)	25
	SUMMONS FOR DOPING CONTROL FORM (D2)	26
	SUMMONS FOR OUT-OF-COMPETITION DOPING CONTROL FORM (D2OOC)	27
	DECLARATION OF MEDICATION FORM (D3)	28
	DOPING CONTROL STATION REGISTER FORM (D4)	29
	DOPING CONTROL STATION REGISTER FORM (D4OOC)	30
	DOPING CONTROL FORM (D5)	31
	PARTIAL SAMPLE FORM (D6)	32
	CHAIN OF CUSTODY AND CONFIRMATION OF RECEIPT BY LABORATORY FORM (D7)	33
APPENDIX E:	DEFINITIONS	34
APPENDIX F:	WHEREABOUTS INFORMATION FOR OUT-OF-COMPETITION TESTING	37

## **Preamble**

Doping has become a constant preoccupation of international sports organisations and national governments.

The fundamental aims of UEFA's doping controls are:

- to uphold and preserve the ethics of sport;
- to safeguard the physical health and mental integrity of football players;
- to ensure that all competitors have an equal chance.

Doping controls were introduced to ensure that the results of the matches in UEFA's competitions are a fair reflection of the strength of the contenders.

## **I Definition**

### **Article 1**

#### **Definition of doping**

- 1.01 Doping is defined as the occurrence of one or more of the anti-doping rule violations set forth in paragraph 2.01 below.

### **Article 2**

#### **Anti-doping rule violations**

- 2.01 The following constitute anti-doping rule violations:

- a) The presence of a prohibited substance or its metabolites or markers in a player's specimen.
- It is each player's personal duty to ensure that no prohibited substance enters his body. Players are responsible for any prohibited substance or its metabolites or markers found to be present in their specimens. Accordingly, it is not necessary that intent, fault, negligence or knowing use on the player's part be demonstrated in order to establish an anti-doping violation under Article 2.
  - Excepting those substances for which a quantitative reporting threshold is specifically identified in the prohibited list, the detected presence of any quantity of a prohibited substance or its metabolites or markers in a player's sample constitutes an anti-doping rule violation.
  - As an exception to the general rule of paragraph 2.01, the prohibited list may establish special criteria for the evaluation of prohibited substances that can also be produced endogenously.

- b) Use or attempted use of a prohibited substance or a prohibited method.

The success or failure of the use of a prohibited substance or prohibited method is not material. It is sufficient that the prohibited substance or prohibited method was used or attempted to be used for an anti-doping violation to be committed.

- c) Refusing, or failing without compelling justification, to submit to sample collection after notification as authorised in these regulations or otherwise evading sample collection.
- d) Violation of applicable requirements regarding player availability for out-of-competition testing, including failure to provide required whereabouts information and missed tests as set out in Appendix F.
- e) Tampering, or attempting to tamper with any part of a doping control.
- f) Possession of prohibited substances and methods:

Possession by a player at any time or place of a substance that is prohibited in out-of-competition testing or a prohibited method unless the player establishes that the possession is pursuant to a Therapeutic Use Exemption granted in accordance with the procedure defined in the circular referred to in 4.03 of the present regulations or other acceptable justification.

Possession of a substance that is prohibited in out-of-competition testing or a prohibited method by player support personnel in connection with a player, competition or training, unless the player support personnel establishes that the possession is pursuant to a Therapeutic Use Exemption granted to a player in accordance with the procedure defined in the circular referred to in 4.03 of the present regulations or other acceptable justification.

- g) Trafficking of any prohibited substance or prohibited method.
- h) Administration or attempted administration of a prohibited substance or prohibited method to any player, or assisting, encouraging, aiding, abetting, covering up or any other type of complicity involving an anti-doping rule violation or attempted violation.

### **Article 3**

#### **Proof of doping**

##### **Burdens and standards of proof**

- 3.01 UEFA has the burden of establishing whether an anti-doping violation has occurred.

##### **Methods of establishing facts and presumptions**

- 3.02 Facts related to anti-doping rule violations may be established by any reliable means, including admissions. The following rules of proof are applicable in doping cases:

WADA-accredited laboratories or as otherwise approved by WADA are presumed to have conducted sample analysis and custodial procedures in accordance with the WADA International Standard for Laboratories. The player may rebut this presumption by establishing that a departure from the International Standard occurred.



If a player rebuts the aforementioned presumption by showing that a departure from the International Standard occurred, then UEFA has the burden of establishing whether such departure caused the adverse analytical finding.

Departures from the rules governing the UEFA doping control procedure which did not cause an adverse analytical finding or other anti-doping rule violation shall not invalidate such results. If the player establishes that departures from the UEFA doping control procedure occurred, UEFA shall have the burden of establishing that such departures did not cause the adverse analytical finding or the factual basis for the anti-doping rule violation.

## **Article 4**

### **Prohibited substances and methods**

- 4.01 Prohibited substances and methods comprise everything on the Prohibited List published by WADA from time to time. The Prohibited List in force is available on WADA's website at [www.wada-ama.org](http://www.wada-ama.org). UEFA will notify national associations and clubs participating in UEFA competitions of any amendments to the Prohibited List in due time by circular letter.

### **Therapeutic Use Exemption (TUE)**

- 4.02 A player may be granted a Therapeutic Use Exemption (TUE) permitting the use of a prohibited substance or method contained in the WADA Prohibited List.
- 4.03 UEFA only considers TUE applications for players of clubs and national associations participating in UEFA competitions. UEFA will issue a circular in due time to notify national associations and clubs participating in UEFA competitions about the specific criteria, conditions and procedure for submitting TUE applications to UEFA. UEFA TUE forms will be enclosed with the circular.
- 4.04 A player may request WADA to review a negative decision by the UEFA TUE Committee within 21 days of notification of such decision. Such a request does not suspend UEFA's decision. Notification may be made by registered letter or fax.
- 4.05 WADA, on its own initiative, may review the granting of a therapeutic use exemption at any time during its duration. WADA will complete its review within 30 days. If the decision regarding the granting of a TUE is reversed on review, the reversal must not apply retroactively.

## **II Doping Control Organisation**

### **Article 5**

#### **Organisation**

- 5.01 The UEFA CEO appoints an Anti-Doping Panel, which consists of members of the Medical Committee as well as external experts. The Anti-Doping Panel proposes the anti-doping programme and policy to the Medical Committee and CEO.
- 5.02 A Doping Control Officers (DCO) Panel is appointed by the CEO. It is composed of doping control officers, who are medical doctors and support the Anti-Doping Panel in the implementation of the anti-doping programme, in particular by carrying out doping controls. The DCOs have the authority to take decisions on the site of the doping control within the framework of these regulations. The DCO may be assisted by a Doping Control Officer Assistant or a Chaperone.
- 5.03 The Anti-Doping Unit deals with the following matters:
- Planning and organisation of in-competition and out-of-competition controls. No advance notice is given of such controls. The unit may order target testing to be conducted.
  - Appointment of DCOs for doping controls.
  - Providing DCOs with the necessary equipment for their tasks and supporting them in administrative matters.
  - DCO training courses.
  - Selection of a WADA-accredited laboratory, or as otherwise approved by WADA, for the analysis of samples. The B sample shall be analysed by the same laboratory that analysed the A sample. However, when specific circumstances so justify, the Anti-Doping Unit may order all or part of a B sample to be analysed at a second WADA-accredited laboratory, or as otherwise approved by WADA. The same instruction may be given for part of an A sample.
  - Results management. In cooperation with the Anti-Doping Panel, the Anti-Doping Unit reviews:
    - any applicable TUE;
    - any alleged irregularity of the testing process or laboratory analysis;
    - the explanation of the player tested or other relevant person;
    - possible follow-up investigations.
  - Administration of TUE applications. The Anti-Doping Unit refers the TUE applications to the UEFA TUE Committee.
- 5.04 The UEFA TUE Committee has the authority to grant, review and cancel TUEs.

- 5.05 The disciplinary bodies (Control and Disciplinary Body, Appeals Body) deal with disciplinary cases arising from the violation of the present anti-doping regulations.

## **Article 6**

### **Obligations of national associations, clubs and players**

- 6.01 Associations and clubs participating in UEFA competitions undertake to assist UEFA in the implementation of its anti-doping programme.
- 6.02 Any player participating in a UEFA competition may be required to undergo a doping control after a match and therefore must remain available until 30 minutes after the end of the match. He may also be required to undergo out-of-competition controls and target testing, even if he is under a period of suspension. Doping controls may include blood and/or urine samples.
- 6.03 Every player designated to undergo a doping control is obliged to undergo any medical examination considered necessary by the DCO, and to cooperate with the latter in this respect.
- 6.04 Every player is personally responsible for reporting immediately to the doping control station as notified.
- 6.05 Every player selected is obliged to provide a sample.
- 6.06 Players from national associations and clubs participating in UEFA competitions shall provide whereabouts information at UEFA's request. The ultimate responsibility for providing whereabouts information rests with each player.
- UEFA will issue a circular in due course to notify national associations and clubs participating in UEFA competitions which players form part of the UEFA out-of-competition testing pool. Teams and/or players in the UEFA out-of-competition testing pool are required to provide up-to-date whereabouts information and, in the case of teams, an up-to-date list of players if requested. Full details of whereabouts information requirements are given in Appendix F: Whereabouts information for out-of-competition testing.
- 6.07 National associations shall assist UEFA in obtaining whereabouts information concerning teams and/or players as requested by UEFA.
- 6.08 Each national association shall assist its national anti-doping organisation in establishing the latter's testing pool of national-level teams and/or players.

## **Article 7**

### **Draw procedure for in-competition controls**

- 7.01 Two players plus two reserves from each team are drawn by lot to undergo a doping control at the doping control station. The Anti-Doping Unit may instruct the DCO on players to be tested.

- 7.02 At all matches where doping controls are to be conducted, the DCO informs the team representatives on his arrival at the match venue. He also explains the procedure for drawing the players to be tested.
- 7.03 The draw is carried out during the half-time interval at a place designated by the DCO, usually in the doping control station.
- 7.04 In addition to the DCO, the UEFA delegate and the team representatives may be present. If the UEFA delegate is unable to attend, the DCO may appoint a witness.
- 7.05 For the draw, the DCO places the numbers that correspond to the shirt numbers of all players of each team into two separate receptacles (one envelope or bag per team). The DCO carefully checks that all player numbers of the players listed on the match sheet are included before placing them into the receptacles.
- 7.06 The DCO draws two counters from each receptacle, plus two counters from each receptacle as a reserve. Without looking at them, the DCO places the first four counters drawn into four separate envelopes (one for each player drawn) and the four reserve counters into four separate envelopes marked "reserve" (again, one for each player). The DCO then seals the envelopes, puts these into one big envelope and keeps the rest of the counters in his possession. The DCO then signs the big envelope, which should be countersigned by the team representatives as well as the UEFA delegate.
- 7.07 The DCO opens the envelopes 15 minutes before the end of the match. At futsal matches, the DCO opens the envelopes after 10 minutes of effective playing time in the second half.
- The team representatives must be present when the envelopes are opened. However, should either or both of them not be present on time, the DCO may proceed.
- 7.08 The DCO completes the Doping Control Draw form (D1), the Doping Control Summons form (D2) and the Declaration of Medication form (D3) with the names and numbers of the players drawn and hands over copies to the team representatives, each of whom must then inform the team doctor concerned.
- 7.09 Where no chaperones are appointed by UEFA, the club or national association concerned is responsible for ensuring that the players drawn to undergo a doping control are taken by the respective team representatives to the doping control station straight from the pitch as soon as the match is over.
- 7.10 The team doctor or his representative completes the Declaration of Medication (D3) for each player selected to undergo a doping control and personally gives the form signed by the player and the doctor to the DCO. If the player in question has taken or been administered any medication in the three months preceding the match, this medication must be declared on the form by the team doctor, giving details of the name of the product, the

diagnosis, the dosage, when and for how long the product was prescribed, as well as the method of administration. Any TUE granted to the player must also be declared on the D3 form.

- 7.11 If a player sustains a serious injury requiring hospital treatment after the draw or is unable to undergo a doping control for any other compelling reason, the first reserve number will be used and the player with that number will be summoned for the doping control. If this player is also seriously injured or unable to undergo a doping control for any other compelling reason, the second reserve draw number will be used. Since it is the responsibility of the DCO to judge a player's inability to undergo a doping control, the team doctor must inform the DCO of any such cases.
- 7.12 If a player is shown a red card at any time during the match, the player must remain available to undergo a doping control after the match if he has been drawn or designated in addition to the draw.

## **Article 8**

### **Draw procedure for out-of-competition controls**

- 8.01 The appointed DCO identifies himself to the head or deputy head of delegation of the relevant team and explains the doping control procedure to him, the team doctor and, if applicable, the coach.

*Comment: When mentioning the DCO, the singular is used. However more than one DCO may be appointed by UEFA to conduct out-of-competition controls depending on the number of players to be tested.*

- 8.02 The DCO checks the players present against the list provided by UEFA and reports to UEFA if any players are absent. The reasons for such absences must be provided by the club and are then entered on the players' list by the DCO.
- 8.03 If the players' list has not been registered with UEFA at the time of the control, the head of delegation gives the DCO an up-to-date list of players, including any who are absent. The reasons for such absences must be provided by the club and are then entered on the players' list by the DCO.
- 8.04 The DCO conducts the draw and/or nominates the players to be tested as decided by the Anti-Doping Unit.
- 8.05 Should a draw take place, the DCO conducts it as follows:
- a) Referring to the players' list mentioned in paragraph 8.02 or 8.03, he checks the names and shirt numbers of the players.
  - b) He spreads out on a table the tags containing the numbers of all the players, including the players not present.
  - c) He makes sure that none of the numbers is missing before placing them in an envelope, bag or similar receptacle.

- d) He then draws as many numbers from his envelope, bag or similar receptacle as instructed by the Anti-Doping Unit.
  - e) For each drawn and/or nominated player not present at the time of the draw, the DCO draws a reserve player.
- 8.06 The DCO indicates on the players' list the players drawn and/or nominated for a doping control, the reserve players and any other relevant information, and completes the Doping Control Summons form (D2 OOC) and the Declaration of Medication form (D3) with the names and numbers of the players drawn, including the reserve players. The DCO gives the team doctor a copy of the D2 OOC and D3 forms.
- 8.07 The team doctor or his representative completes the Declaration of Medication (D3) form for each player selected to undergo a doping control and personally gives the form signed by the player and the doctor to the DCO. If the player in question has taken or been administered any medication in the three months preceding the match, this medication must be declared on the form by the team doctor, giving details of the name of the product, the diagnosis, the dosage, when and for how long the product was prescribed, and the method and frequency of administration. Any TUE granted to the player must also be declared on the D3 form.
- 8.08 The club or national association concerned is responsible for ensuring that the players drawn to undergo a doping control are informed and instructed to report to the doping control station within 60 minutes of being notified.
- 8.09 The reserve player will only be tested if the missing player fails to report (within 60 minutes of being notified), unless the reserve player offers to provide a sample beforehand. By so doing, the reserve player concerned agrees that his sample will be valid for testing by UEFA even if the missing player reports in time and provides his sample.
- 8.10 Should a player drawn for testing fail to report to the doping control station in time, the DCO will submit a missed test report to UEFA. In such cases, the first reserve player drawn will be used and will be summoned for the doping control. Should a second player drawn for testing fail to report to the doping control station in time, the second reserve player drawn will be used, and so on.

## **Article 9**

### **Suspicion of doping**

- 9.01 If doping is suspected, the UEFA delegate and/or the referee and/or the DCO are entitled to summon additional players to be tested.

## **Article 10**

### **Doping control station**

- 10.01 The doping control station must comply with the requirements set out in Appendix B of these regulations.
- 10.02 Apart from the players drawn to undergo a doping control and the team representative accompanying them, only the following persons will be allowed access to the doping control station:
- a) the DCO;
  - b) the doping control liaison officer of the home team;
  - c) the local doping control officer(s) (if applicable);
  - d) the UEFA delegate or another UEFA official;
  - e) an interpreter approved by the DCO (if necessary).
- Anyone else entering and/or leaving the doping control station must record their arrival and/or departure by signing the Doping Control Station Register form (D4) provided by the DCO.
- 10.03 The players selected remain in the doping control station until they are ready to provide a sample.
- 10.04 Drinks that are free of doping substances are made available to the players in the form of unopened and sealed glass bottles or cans in a refrigerator in the doping control station. If a player wishes to take his own food and drinks to the doping control station, it is entirely at his own responsibility.
- 10.05 The DCO may order security officers or stewards to ensure that non-authorised persons do not enter the doping control station.

## **Article 11**

### **Doping control procedure for urine samples**

- 11.01 The DCO supervises the doping control procedure. He checks the player's identity by means of the Doping Control Summons form (D2) and asks the player to identify himself. He explains the procedure for the collection of samples and informs the player of his rights and obligations.
- 11.02 The player first selects a clean and previously unused urine collection beaker for the samples.
- 11.03 The player then selects two clean and previously unused transparent glass bottles (one for the A sample and the other the B sample). Each bottle will bear the same code number.
- 11.04 The player urinates into the collection beaker under the strict supervision of the DCO, who must be of the same gender as the player.

- 11.05 The volume of urine must be at least 75 ml (A 50 ml, B 25 ml). If the player is unable to provide 75 ml, 60 ml (A 35 ml, B 25 ml) will suffice, unless the DCO decides otherwise.
- 11.06 The player decides whether he or the DCO will pour the urine into bottles A and B. If the player decides to do so himself, the DCO explains the procedure to him.
- 11.07 A sufficient volume of urine should be left in the collection beaker to allow the DCO to test the pH and gravity of the sample. These are then recorded on the Doping Control form (D5).
- 11.08 The player and the DCO check that the bottles are in good and proper condition. The urine sample is poured into bottles A and B and the player or the DCO closes them tightly. The player ensures that no urine can leak out and compares the code numbers on both bottles, the bottle caps and the particulars on the D5 form once again.
- 11.09 The DCO then completes the Doping Control form (D5), which must be signed by the player, the team representative accompanying him and the DCO. On this same form, the player should also clearly indicate the name and address to which he wishes the test result to be sent. If there is no indication or the writing is not legible, the test result will be sent to the club or national association's address. The signatures of the player and the DCO are legally binding. One copy of this form is retained by the DCO, one by the UEFA Administration, one by the player, and one by the laboratory. By signing the D5 form, the player confirms that, subject to any concerns recorded by the player in the "Remarks" section, the testing was conducted in accordance with the present regulations and that no subsequent complaint is possible.
- 11.10 The A and B samples of all the players tested and the corresponding copies of the forms are delivered to the laboratory.

**Procedure if the stipulated urine volume of 75 ml is not obtained**

- 11.11 If the urine sample provided is less than 75 ml, the player or the DCO pours the volume of urine already collected into the bottle marked A and seals this bottle with the interim sealing device before replacing the cap on the bottle. Next, bottle A is placed back in the polystyrene foam packaging, which also contains bottle B, and sealed with the security tape.
- 11.12 The number of the security tape and the quantity of urine collected (in ml) must be written on the Partial Sample form (D6) provided for this purpose. The player must sign both parts (main part and detachable part) of the D6 form to confirm that the code number is correct on both parts. The name of the player must be written on the main part of the form.
- 11.13 When the player is able to provide an additional sample, he must identify his initial sample by checking the code number on the security tape on the



polystyrene foam packaging against the number on the Partial Sample form (D6). The DCO double-checks this as well.

- 11.14 The player and the DCO check together that the security tape has not been broken.
- 11.15 The player then urinates again into a clean, unused beaker.
- 11.16 Under the supervision of the DCO, the player opens the bottle himself by unscrewing the interim sealing device.
- 11.17 The partial sample in the bottle marked A is added to the second sample in the collection beaker to ensure that both samples are properly mixed. If the volume is still insufficient, the steps outlined in paragraphs 11.11 to 11.16 are repeated. Once the required volume is obtained, testing can continue as from paragraph 11.06 to 11.10.

### **Property of samples**

- 11.18 Samples collected under the present regulations become the property of UEFA upon collection.

## **Article 12**

### **Analysis of samples**

- 12.01 Samples must be sent for analysis only to WADA-accredited laboratories or as otherwise approved by WADA.
- 12.02 Samples are delivered to the UEFA-designated laboratory by the DCO or by a courier service. The Head of the Anti-Doping Unit or his nominee decides on the appropriate means of transport. The Chain of Custody and Confirmation of Receipt by the Laboratory form (D7) must be completed by the DCO and signed by the laboratory.
- 12.03 The laboratory proceeds with the analysis of the A sample and stores the B sample in conformity with the International Standard for Laboratories.
- 12.04 UEFA endeavours to ensure that the analysis of A samples is carried out as soon as possible after arrival at the designated laboratory.
- 12.05 The laboratory communicates all negative test results to the Head of the Anti-Doping Unit or his nominee as soon as these results have been confirmed.
- 12.06 If the analysis of the A sample produces a negative result, the B sample is disposed of by the laboratory within the time limit specified in the WADA International Standard for Laboratories.

## **Article 13**

### **Procedure if sample A produces an adverse analytical finding**

- 13.01 If the A sample produces an adverse analytical finding, the laboratory must inform the Head of the Anti-Doping Unit or his nominee immediately and confidentially by telephone. The original full analytical report must be sent to

the Head of the Anti-Doping Unit or his nominee by recorded delivery and marked "private and confidential".

- 13.02 On receipt of confirmation of an adverse analytical finding with the A sample, the Head of the Anti-Doping Unit or his nominee confidentially informs the general secretary of the national association or club concerned or any other qualified representative by telephone in due course. The general secretary of the national association or club concerned or any other qualified representative must immediately inform the player. The Head of the Anti-Doping Unit or his nominee then informs the player about the results in writing at the national association's or club's address, unless another address is indicated on the Doping Control form. A copy of the laboratory's findings will be enclosed. The general secretary of the national association or club concerned or any other qualified representative receives a copy of this letter.

## **Article 14**

### **Right to request an analysis of sample B**

- 14.01 If there is an adverse analytical finding with the A sample, the player is entitled to request an analysis of the B sample within 48 hours of receiving the registered letter. At UEFA European Championship final tournaments, the 48-hour deadline may be reduced. The participating national associations will be informed by means of a circular letter before the start of the tournament.
- 14.02 Requests for analysis of the B sample must be submitted in writing. If the player does not request analysis of the B sample, he is considered to have fully recognised and accepted the results of the A sample.
- 14.03 If analysis of the B sample is requested, UEFA communicates this request immediately to the head of the laboratory where the B sample is being stored. The B sample analysis takes place at the same laboratory as soon as possible, by personnel who were not directly involved in the analysis of the A sample. Both the player and the general secretary of the national association or club concerned are informed of the time at which the B sample is to be opened.
- 14.04 In accordance with the International Standard for Laboratories, the Chairman of the Anti-Doping Panel or his appointed representative, as well as the player or his appointed representative, may be present at the laboratory when the bottle containing the B sample is opened and analysed. All costs incurred as a result of the presence of the player or his representative at the laboratory when the B sample is opened must be covered by the player, his club or national association.
- 14.05 The results of the B sample analysis must be communicated to the Head of the Anti-Doping Unit or his nominee immediately and confidentially by telephone. The original analytical report on the B sample must be sent to the

Head of the Anti-Doping Unit or his nominee by recorded delivery and must be marked "private and confidential".

- 14.06 Unless the Head of the Anti-Doping Unit or his nominee requests otherwise in writing, the laboratory must destroy the B sample the day following the minimum period that the laboratory is required to keep the sample under the International Standard for Laboratories.

## **Article 15**

### **Procedure if sample B confirms the A sample**

- 15.01 If the laboratory report reveals the presence of the same prohibited substance or the use of the same prohibited method in the B sample as was detected in the player's A sample, an anti-doping rule violation will be deemed to have been committed. The same conclusion applies in the event of the player admitting to having committed a doping offence or waiving his right to a B sample analysis.
- 15.02 UEFA is not liable for any consequences of a B sample analysis that does not confirm the adverse analytical finding of the A sample and is therefore declared negative.

## **Article 16**

### **Doping control procedure for blood samples**

- 16.01 The DCO is responsible for blood sampling. He may not delegate the sampling procedure to his assistants unless they are qualified phlebotomists.
- 16.02 The DCO draws players in accordance with the procedure set out in article 7 or 8 of the present regulations according to whether the control is in or out of competition. A player may have to provide a urine sample in addition to the blood samples.
- 16.03 If a urine sample is also required, the collection of blood samples from the player is, in general, carried out first, before the player provides a urine sample.
- 16.04 If a urine sample is also required, part of the doping control station is partitioned off to carry out the blood sampling procedure.
- 16.05 Blood is drawn from the player's vein, preferably from the inner part of the lower arm, while the player is sitting on a chair and resting his arm on a suitable support.
- 16.06 Blood samples are taken by means of a proficient (lege artis) intravenous puncture, which entails no health risk, except the possible risk of local haematomas.
- 16.07 The player is allowed to select the required blood sample kit. All the collection material will have the same code number.

16.08 At the beginning of the doping control procedure, the DCO explains the blood collection procedure to the selected player with the help of the team doctor.

16.09 Medical declarations are required for:

- medication that may affect the venepuncture procedure (particularly those that affect clotting) e.g. aspirin, non-steroidal anti-inflammatory agents;
- any bleeding disorder which may have an effect on clotting time;
- any blood transfusions in the last six months (to be declared on the *Doping Control form*).

Prior to the blood samples being taken, the player is asked if he has understood the procedure and purpose of sampling. If he has taken medication which could affect clotting time, extra care is taken with regard to haemostasis.

16.10 The DCO is responsible for:

- hygiene and a sterile technique;
- handling of blood-sampling equipment;
- handling of blood samples e.g. mixing anti-coagulants;
- after-care for the players.

The DCO or his assistants wears sterile gloves during the procedure and only the DCO, his assistant and the players are allowed to handle the samples.

16.11 The player decides whether he or the DCO seals the blood samples into the special bottle once the DCO or his assistant has completed the blood-collection procedure. The DCO then places the coded, sealed glass bottle containing the player's blood samples into the transport cool bag.

16.12 The player may be accompanied by an official team representative at all times, preferably the team doctor.

16.13 Blood samples are taken following the usual clinical procedure for blood collection. At least 3ml of blood is collected in each of two venepuncture tubes (3ml as the A sample; 3 ml as the B sample). If required, the procedure is repeated and more blood is collected from the same puncture in 3ml venepuncture tubes.

16.14 If a player's vein collapses after a small amount of blood has been collected, the procedure is repeated on the other arm to obtain a sufficient volume of blood before packing it in the Bereg Kit.

16.15 Blood tests must be analysed by WADA-accredited laboratories or as otherwise approved by WADA. Results are communicated in the same way as urine test results.

### **Property of samples**

16.16 Samples collected under the present regulations become the property of UEFA upon collection.

## **Article 17**

### **Disciplinary procedure in the event of anti-doping rule violations**

- 17.01 In cases of anti-doping rule violations, UEFA will instigate disciplinary proceedings against the parties concerned in accordance with the UEFA Disciplinary Regulations. This may include the granting of provisional measures.
- 17.02 Any player penalised for a doping offence may be ordered to undergo further doping controls.
- 17.03 Where one or more players in a team have been notified of a possible anti-doping rule violation in conformity with the present regulations in connection with an event, the team may be subjected to target testing.
- 17.04 UEFA reserves the right to publicise anti-doping rule violations and their consequences.

## **III Further provisions**

### **Article 18**

#### **Court of Arbitration for Sport**

- 18.01 In case of litigation resulting from or in relation to these regulations, the provisions regarding the Court of Arbitration for Sport (CAS) laid down in the UEFA Statutes apply.

### **Article 19**

#### **Closing provisions**

- 19.01 In the present regulations, the masculine form refers to either gender.
- 19.02 Any matter not provided for in these regulations will be settled by the CEO in consultation with the Anti-Doping Panel. All such decisions are final.
- 19.03 If there is any discrepancy in the interpretation of the English, French or German versions of these regulations, the English version prevails.
- 19.04 The present regulations are implemented and construed according to Swiss law and the rules of the Court of Arbitration of Sport (CAS) in Lausanne.
- 19.05 The present regulations apply to any anti-doping rule violation committed after they have come into force.

19.06 The present regulations come into force on 5 June 2006.

For the UEFA Executive Committee:

Lennart Johansson  
President

Lars-Christer Olsson  
Chief Executive

Nyon, 22 March 2006


## **APPENDIX A: Instructions to organisers of UEFA matches**

1. For each match, the home team appoints a Doping Control Liaison Officer whose duty is to remain at the disposal of the DCO. This Doping Control liaison officer does not need to be medically trained. He should, however, be able to speak English and must remain available until the doping control has been completed. He also organises transport for the DCO back to his hotel on completion of the doping control.
2. The home team must provide a room for doping control purposes (doping control station). It must be near the players' dressing rooms and inaccessible to the public and the media. It must be at least 20m<sup>2</sup> and comprise a waiting room, a testing room and a toilet, all adjoining.
  - a) The testing room must contain:
    - table (1)
    - chairs (4)
    - sink with running water
    - toiletries (soap, towels, etc.)
    - cabinet with a lock
    - toilet (adjacent to the room or in the room itself).
  - b) The toilet area should be within the testing room, or immediately next to it and with direct private access to the testing room, and must contain:
    - WC with seat
    - sink with running water
    - shower (if possible).
  - c) The waiting room forms part of (a partition dividing the two areas is also acceptable) or is immediately adjacent to the testing room and must contain:
    - sufficient seating for 8
    - clothes-hanging facilities or lockers for 4 (if possible)
    - refrigerator
    - television set (if possible).
3. An assortment of drinks, free of doping substances, in their original containers and in the form of unopened and sealed glass bottles or cans must be provided in a refrigerator in the waiting room of the doping control station (approx. 10 litres of mineral still water, 12 cans of caffeine-free soft drinks and approx. 12 cans of non-alcoholic beer).
4. A top-category seat must be reserved for the DCO in the directors' box or equivalent. This seat should be located near the seat reserved for the UEFA delegate and must provide easy access to the doping station.

5. Stewards at the main stadium gates must be informed that persons who identify themselves as DCOs and who show special UEFA passes with their photograph are to be granted free access to the stadium.
6. The DCO may order security officers or stewards to ensure that non-authorised persons do not enter the doping control station.



## APPENDIX B: Plan of Doping Control Station



## **APPENDIX C: List of WADA-accredited laboratories in Europe**

### **AUSTRIA**

*Head of laboratory:*

***Dr Günter GMEINER***

### **ARC Seibersdorf research GmbH**

#### **Doping Control Laboratory**

AT - 2444 Seibersdorf

Austria

Tel. +43 50 550 35 39

Fax +43 50 550 35 66

E-mail : guenter.gmeiner@arcs.ac.at

### **BELGIUM**

*Head of laboratory:*

***Prof. Dr F.T. DELBEKE***

### **DoCoLab Universit t Gent-UGent**

Technologiepark 30

BE - 9052 Zwijnaarde

Belgium

Tel. +32 9 331 32 90

Fax +32 9 331 32 99

E-mail : frans.delbeke@Ugent.be

### **CZECH REPUBLIC**

*Head of laboratory:*

***Dr R. SLECHTOVA***

### **General Faculty Hospital**

#### **Department of Doping Control**

Nehvizdska 8

CZ -198 00 Prague 9

Czech Republic

Tel. +420 2 818 62 332

Fax +420 2 818 62 332

E-mail: odkusm@mbox.vol.cz

### **ENGLAND**

*Head of laboratory :*

***Prof. David COWAN***

### **Drug Control Centre**

#### **King's College London**

The Franklin-Wilkins Building

150 Stamford Street

GB – London SE1 9NH

England

Tel. +44 20 7848 48 48

Fax +44 20 7848 49 80

E-mail : david.cowan@kcl.ac.uk

**ENGLAND**

*Head of laboratory:*

**Mr. Steve MAYNARD**

**Drug Surveillance Group  
HFL Ltd**

Newmarker Road  
GB - Cambridge, Cb7 5WW  
Great Britain  
Tel. +44 1638 720500  
Fax. +44 1638 724200  
E-mail: SMaynard@hfl.co.uk

**FINLAND**

*Head of laboratory:*

**Mr. Antti LEINONEN**

**Doping Control Laboratory  
United Laboratories Ltd - Helsinki**

Höyläämötie 14  
FI - 00380 Helsinki  
Finland  
Tel. +358 9 50 60 54 42  
Fax +358 9 50 60 54 20  
E-mail : antti.leinonen@yhtyneetlaboratoriot.fi

**FRANCE**

*Head of laboratory:*

**Prof. Jacques de CEAURRIZ**

**Laboratoire National de Dépistage du Dopage  
CREPS**

143, avenue Roger Salengro  
FR - 92290 Châtenay-Malabry  
France  
Tel. +33 1 46 60 28 69  
Fax +33 1 46 60 30 17  
E-mail: direction@lndd.com

**GERMANY**

*Head of laboratory:*

**Prof. Wilhelm SCHÄNZER**

**Laboratory for Doping Analysis  
German Sports University Cologne**

Carl-Diem-Weg 6  
DE - 50933 Köln  
Germany  
Tel. +49 221 497 1313  
Fax +49 221 497 32 36  
E-mail: schaenzer@biochem.dshs-koeln.de

**GERMANY**

*Head of laboratory:*

**Prof. R. K. MÜLLER**

**Institut of Dopinganalytik und Sportbiochemie**

Dresdner Strasse 12  
DE - 01731 Kreischa b. Dresden  
Germany  
Tel. +49 352 062 060  
Fax +49 352 062 06 20  
E-mail: rkmuller.leipzig@t-online.de  
info@idas-kreischa.de

**GREECE****Head of laboratory:****Dr Costas****GEORGAKOPOULOS****Doping Control Laboratory of Athens**

OAKA, Kifissias 37.

GR - 15123 Maroussi

Greece

Tel. +30 210 683 34567

Fax +30 210 683 4021

Email : oaka@ath.fortnet.gr

**ITALY****Head of laboratory:****Dr Francesco BOTRÈ****Laboratorio Antidoping**

Federazione Medico Sportiva Italiana

Largo Giulio Onesti 1

IT - 00197 Rome RM

Italy

Tel. +39 06 808 30 11

Fax +39 06 807 89 71

E-mail: francesco.botre@uniroma1.it

**NORWAY****Head of laboratory:****Prof. Dr. Peter****HEMMERSBACH****Hormone Laboratory****Section for Doping Analysis****Aker University Hospital**

Trondheimsveien 235

NO - 0514 Oslo

Norway

Tel. +47 22 89 43 68 / 22 89 40 07

Fax +47 22 89 41 51

E-mail: peter.hemmersbach@farmasi.uio.no  
doping@H-lab.no**POLAND****Head of laboratory:****Ms. Dorota KWIATKOWSKA****Department of Anti-Doping****Research Institute of Sport**

Trylogi 2/16

01-982 Warsaw

Poland

Tel +48 22 834 94 05

Fax +48 22 835 09 77

E-mail: antydoping.dep@insp.waw.pl

Dorota.kwiatkowskansp.waw.pl

**PORTUGAL**

***Head of laboratory:***

***Prof. Xavier de la TORRE***

**Laboratório e Análises e Dopagem  
Instituto do Desporto de Portugal**

Av. Professor Egas Moniz  
Estádio Universitário  
PT - 1600-190 Lisboa  
Portugal  
Tel. +351 21 796 90 73  
Fax +351 21 797 75 29  
E-mail : lad@idesporto.pt

**RUSSIA**

***Head of laboratory:***

***Dr Grigory RODCHENKOV***

**Antidoping Centre Moscow**

Elizavetinskii projezd, 10  
RU - 107005 Moscow  
Russia  
Tel +7 095 261 92 22  
Fax +7 095 267 73 20  
E-mail : grodchen@yandex.ru

**SPAIN**

***Head of laboratory:***

***Prof. Jordi SEGURA***

**Institut Municipal d'Inverstigacio Medica  
Unitat de Farmacologia**

c/ Doctor Aiguader, 80  
ES - 08003 Barcelona  
Spain  
Tel +34 93 221 10 09  
Fax +34 93 221 32 27  
E-mail : jsegura@imim.es

**SPAIN**

***Head of laboratory:***

***Dr Augustin-Francisco  
RODRIGUEZ CANO***

**Laboratorio de Control del Dopaje  
del Consejo Superior de Deportes**

c/ El Greco, s/n  
ES - 28040 Madrid  
Spain  
Tel +34 91 589 68 90 / 88  
Fax +34 91 543 72 90  
Augustinf.rodriquez@csd.mec.es

**SWEDEN*****Head of laboratory:******Dr Mats GARLE*****Doping Control Laboratory  
Karolinska University Hospital**

Huddinge

C2-66

SE - 141 86 Stockholm

Sweden

Tel. +46 8 58 58 10 75 / 77

Fax +46 8 58 58 10 76

E-mail: [dopinglab@karolinska.se](mailto:dopinglab@karolinska.se)[mats.garle@karolinska.se](mailto:mats.garle@karolinska.se)**SWITZERLAND*****Head of laboratory:******Dr Martial SAUGY*****Laboratoire Suisse d'Analyse du Dopage**

Chemin des Croisettes 22

CH – 1066 Epalinges

Switzerland

Tel. +41 21 314 73 30

Fax +41 21 314 73 33 / 70 95

E-mail : [lad.central@chuv.ch](mailto:lad.central@chuv.ch)[Martial.Saugy@chuv.ch](mailto:Martial.Saugy@chuv.ch)**TURKEY*****Head of laboratory:******Prof. M. A TEMIZER*****Turkish Doping Control Centre**

Hacettepe University

TR-06100 Ankara

Turkey

Tel. +90 312 310 67 76/ or +90 312 305 21 56

Fax. +90 312 305 20 62

Email: [aytekint@hacettepe.edu.tr](mailto:aytekint@hacettepe.edu.tr)[Tdkmmaster@hacettepe.edu.tr](mailto:Tdkmmaster@hacettepe.edu.tr)

# APPENDIX D: Forms

## Doping Control Draw form (D1)



**Doping Control Draw**  
*Contrôle antidopage – Tirage au sort*  
*Dopingkontrolle – Auslosung*

Union des associations européennes de football

Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31



COMPETITION / COMPÉTITION / WETTBEWERB			
UEFA Champions League		European Women's Championship	
UEFA Cup		European Women's Under-19 Championship	
UEFA Intertoto Cup		UEFA Women's Cup	
UEFA European Football Championship™		European Futsal Championship	
European Under-21 Championship		European Futsal Cup	
European Under-17 Championship		Region's Cup	
European Under-19 Championship		Meriden Cup	
HOME TEAM / EQUIPE RECEVANTE / HEIMMANNSCHAFT			
Shirt numbers of the players drawn Numéros de maillot des joueurs tirés au sort Ausgeloste Spielernummern		and et und	
First reserve number Premier numéro de réserve Erste Reservenummer			
Second reserve number Deuxième numéro de réserve Zweite Reservenummer			
AWAY TEAM / EQUIPE VISITEUSE / GASTMANNSCHAFT			
Shirt numbers of the players drawn Numéros de maillot des joueurs tirés au sort Ausgeloste Spielernummern		and et und	
First reserve number Premier numéro de réserve Erste Reservenummer			
Second reserve number Deuxième numéro de réserve Zweite Reservenummer			

NAME(S) OF THE PERSON(S) WHO CARRIED OUT THE DRAW NOM(S) DE LA (DES) PERSONNE(S) AYANT EFFECTUÉ LE TIRAGE AU SPORT NAME(N) DER PERSON(EN), WELCHE DIE AUSLOSUNG DURCHGEFÜHRT HAT (HABEN)

# Summons for Doping Control form (D2)



## Summons for Doping Control Convocation au contrôle antidopage Aufforderung zur Dopingkontrolle

Union des associations européennes de football

Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31



Venue  
Lieu du match  
Austragungsort

Match	Date
Match	Date
Spiel	Datum

Name of UEFA Doping Control Officer  
Nom du contrôleur antidopage de l'UEFA  
Name des UEFA-Dopingkontrollleurs

Player's surname  
Nom du joueur  
Name des Spielers

Player's First Name  
Prénom du joueur  
Vorname des Spielers

Team	Player's number
Equipe	N° du joueur
Mannschaft	Nr. des Spielers

**You have been selected to undergo a doping control and are requested to come immediately after the end of the match, to the doping control station.**

**Vous avez été désigné pour subir un contrôle antidopage et vous êtes prié de vous présenter immédiatement après la fin du match dans le local de contrôle antidopage.**

**Sie wurden für einen Dopingtest ausgewählt und werden gebeten, sich unmittelbar nach Spielschluss in der Dopingkontrollstation einzufinden.**

**You may be accompanied by the doctor, coach or any other team official.**

**Vous pouvez vous faire accompagner par le médecin, l'entraîneur ou le responsable de votre équipe.**

**Sie können sich von Ihrem Arzt, Trainer oder Betreuer begleiten lassen.**

**Refusal to undergo a doping control or attempts to manipulate it shall have the same consequences as positive result.**

**Refuser de se présenter à un contrôle antidopage ou essayer de le manipuler aurait les mêmes conséquences qu'en cas de résultat positif.**

**Die Verweigerung einer Dopingkontrolle oder der Versuch einer Manipulation haben die gleichen Konsequenzen wie ein positiver Befund.**

Signature of the player  
Signature du joueur  
Unterschrift des Spielers

Time of notification  
Heure de notification  
Empfangsbestätigung (Zeit)

Chaperone (escort) Name  
Nom de l'accompagnateur (escorte)  
Name der Begleitperson

Chaperone (escort) Signature  
Signature de l'accompagnateur (escorte)  
Unterschrift der Begleitperson

Signature of the UEFA Doping Control Officer  
Signature du contrôleur antidopage de l'UEFA  
Unterschrift des UEFA-Dopingkontrollleurs



Summons for Out-of-competition Doping Control form (D20OCT)



Summons for Out-of-competition Doping Control  
Convocation au contrôle antidopage hors compétition  
Aufforderung zur Dopingkontrolle ausserhalb von Wettbewerben



Union des associations européennes de football  
Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31

- ☐ Drawn Player  
Joueur tiré au sort  
Ausgeloster Spieler
- ☐ Drawn Reserve Player  
Joueur de réserve tiré au sort  
Ausgeloster Reservespieler

Venue Lieu Ort	
Team Equipe Mannschaft	Date Date Datum
Name of UEFA Doping Control Officer Nom du contrôleur antidopage de l'UEFA Name des UEFA-Dopingkontrollleurs	
Player's surname Nom du joueur Name des Spielers	
Player's First Name Prénom du joueur Vorname des Spielers	
Player's number N° du joueur Nr. des Spielers	

<b>You have been selected to undergo an out-of-competition doping control and are requested to come within 60 minutes of notification to the doping control station.</b>	<b>Vous avez été désigné pour subir un contrôle antidopage hors compétition et vous êtes prié de vous présenter au plus tard 60 minutes après avoir été notifié dans le local de contrôle antidopage.</b>	<b>Sie wurden für einen Dopingtest ausserhalb von Wettbewerben ausgewählt und werden gebeten, sich innerhalb von 60 Minuten nach Erhalt der Mitteilung in der Dopingkontrollstation einzufinden.</b>
<b>You may be accompanied by the doctor, coach or any other team official.</b>	<b>Vous pouvez vous faire accompagner par le médecin, l'entraîneur ou le responsable de votre équipe.</b>	<b>Sie können sich von Ihrem Arzt, Trainer oder Betreuer begleiten lassen.</b>
<b>Refusal to undergo a doping control or attempts to manipulate it shall have the same consequences as positive result.</b>	<b>Refuser de se présenter à un contrôle antidopage ou essayer de le manipuler aurait les mêmes conséquences qu'en cas de résultat positif.</b>	<b>Die Verweigerung einer Dopingkontrolle oder der Versuch einer Manipulation haben die gleichen Konsequenzen wie ein positiver Befund.</b>

Signature of the player Signature du joueur Unterschrift des Spielers	Time of notification Heure de notification Empfangsbestätigung (Zeit)
Team representative name Nom du responsable d'équipe Name des Teamverantwortlichen	Team representative signature Signature du responsable d'équipe Unterschrift des Teamverantwortlichen
Signature of the UEFA Doping Control Officer Signature du contrôleur antidopage de l'UEFA Unterschrift des UEFA-Dopingkontrollleurs	

# Declaration of Medication form (D3)



## Declaration of Medication Déclaration des médicaments Medikationserklärung

Union des associations européennes de football

Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31

☐ In competition  
En compétition  
In Wettbewerb

☐ Out-of-competition  
Hors compétition  
Ausserhalb von Wettbewerben

Team  
Equipe  
Mannschaft

Name of team doctor  
Nom du médecin d'équipe  
Name des Mannschaftsarztes

certifies that the player listed below  
took or was administered the medication  
or treatment indicated:

certifie que le joueur mentionné ci-après  
a pris ou a reçu les médicaments ou  
le traitement suivants:

bescheinigt, dass der unten aufgeführte Spieler  
die folgenden Medikamente eingenommen hat  
bzw. dass diese ihm verabreicht wurden oder  
dass er die folgende Behandlung bekommen hat:

The player has a: (tick appropriate box)  
Le joueur est au bénéfice d'une (cocher la case appropriée):  
Der Spieler hat eine (Zutreffendes ankreuzen):

- ☐ TUE (Therapeutic Use Exemption)/AUT (Autorisation d'usage à des fins thérapeutiques)/ATZ (Ausnahmebewilligung zu therapeutischen Zwecken)  
☐ ATUE (abbreviated Therapeutic Use Exemption)/AUT abrégée (Autorisation d'usage à des fins thérapeutiques abrégée)/  
Ausnahmebewilligung zu therapeutischen Zwecken (Abgekürztes Verfahren)

To what anti-doping organisation was the TUE or ATUE request sent to?  
A quelle organisation antidopage la demande d'AUT ou d'AUT abrégée a été envoyée?  
An welche Antidoping-Organisation wurde der ATZ-Antrag oder abgekürztes Verfahren geschickt?

When was the TUE or ATUE request sent (date)?  
Quand cette demande d'AUT ou d'AUT abrégée a-t-elle été envoyée (date)?  
Wann wurde der ATZ-Antrag oder abgekürztes Verfahren abgeschickt (Datum)?

When did the player received a certificate or acknowledgement of receipt of TUE or ATUE (date)?  
Quand le joueur a-t-il reçu un certificat ou accusé de réception d'une AUT ou AUT abrégée (date)?  
Wann hat der Spieler ein ATZ-Zertifikat oder ATZ-Empfangsbestätigung (abgekürztes Verfahren) erhalten (Datum)?

What prohibited substance(s)?  
Quelle(s) substance(s) interdite(s)?  
Beantragte Substanz(en)?

All other substances used are declared hereunder:  
Toute autre substance est déclarée ci-dessous:  
Alle anderen Substanzen sind nachstehend deklariert:

Player number Joueur n° Spieler Nr.	Surname Nom Name	First name Prénom Vorname		
Diagnosis Diagnostic Diagnose	Name of medication Nom du médicament Name des Medikaments	Substance Substance Substanz	Dosage Dosage Dosierung	Frequency of administration Fréquence d'administration Häufigkeit der Verabreichung

Caution: for glucocorticosteroids declare any administration in the last 3 months  
Attention: toute administration de glucocorticostéroïdes effectuée au cours des 3 derniers mois doit être déclarée.  
Vorsicht: Bei Glukokortikosteroiden jede Verabreichung innerhalb der letzten 3 Monate angeben.

I hereby confirm that I have taken/been administered the medication listed above.  
Je confirme par la présente que j'ai pris ou que le médecin d'équipe m'a administré les médicaments ci-dessus.  
Ich bestätige hiermit, dass ich vor dem Spiel die oben aufgeführten Medikamente eingenommen habe oder sie mir verabreicht wurden.

Signature of the player  
Signature du joueur  
Unterschrift des Spielers

Signature of the team doctor  
Signature du médecin de l'équipe  
Unterschrift des Mannschaftsarztes

Signature of the UEFA Doping Control Officer  
Signature du contrôleur antidopage de l'UEFA  
Unterschrift des Dopingkontrollieurs der UEFA

Date  
Date  
Datum

D3

Doping Control Station Register form (D4)



Doping Control Station Register  
Registre du local du contrôle antidopage  
Dopingkontrollstation



Union des associations européennes de football  
Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31

Match  
Match  
Spiel

Competition  
Compétition  
Wettbewerb

Date  
Date  
Datum

In addition to the persons mentioned in article 10.02 of the UEFA anti-doping regulations, the following persons were present in the doping control station during the control conducted at the above match:

En plus des personnes mentionnées dans l'article 10.02 du règlement antidopage de l'UEFA, les personnes suivantes étaient présentes dans le local de contrôle antidopage pendant le contrôle lors du match susmentionné:

Zusätzlich zu den in Absatz 10.02 des UEFA-Dopingreglements erwähnten Personen, waren die folgenden Personen während der beim obgenannten Spiel durchgeführten Kontrolle in der Dopingkontrollstation anwesend:

Name of person Nom de la personne Name der Person	Function Fonction Funktion	Time of arrival Heure d'arrivée Ankunftszeit	Time of departure Heure de départ Uhrzeit beim Verlassen des Raumes	Signature (on departure) Signature (lors du départ) Unterschrift (beim Verlassen des Raumes)

Doping Control Station Register form (D4OOCT)



Doping Control Station Register  
Registre du local du contrôle antidopage  
Dopingkontrollstation



Union des associations européennes de football  
Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31

Venue  
Lieu  
Ort

Out-of-competition doping control  
Contrôle anti-dopage hors compétition  
Dopingkontrolle ausserhalb von Wettbewerben

Date  
Date  
Datum

In addition to the persons mentioned in article 10.02 of the UEFA anti-doping regulations, the following persons were present in the doping control station during the out-of-competition control:

En plus des personnes mentionnées dans l'article 10.02 du règlement antidopage de l'UEFA, les personnes suivantes étaient présentes dans le local de contrôle antidopage pendant le contrôle hors compétition :

Zusätzlich zu den in Absatz 10.02 des UEFA-Dopingreglements erwähnten Personen waren die folgenden Personen während der Dopingkontrolle ausserhalb von Wettbewerben in der Dopingkontrollstation anwesend:

Name of person Nom de la personne Name der Person	Function Fonction Funktion	Time of arrival Heure d'arrivée Ankunftszeit	Time of departure Heure de départ Uhrzeit beim Verlassen des Raumes	Signature (on departure) Signature (lors du départ) Unterschrift (beim Verlassen des Raumes)

D4 OOCT

# Doping Control form (D5)



## Doping Control Contrôle antidopage Dopingkontrolle



Union des associations européennes de football

Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31

☐ In competition  
En compétition  
In Wettbewerb

☐ Out-of-competition  
Hors compétition  
Auserhalb von Wettbewerben

☐ Female  
Femme  
Frau

☐ Male  
Homme  
Mann

Venue  
Lieu du match  
Austragungsort

Match  
Match  
Spiel

Date  
Date  
Datum

UEFA Doping Control Officer  
Contrôleur antidopage de l'UEFA  
UEFA-Dopingkontrollleur

Full name of the player  
Nom et prénom du joueur  
Name und Vorname des Spielers

Date of birth  
Date de naissance  
Geburtsdatum

Address to which result should be sent:  
Adresse à laquelle le résultat doit être envoyé:  
Adresse zur Resultatsübermittlung:

☐ To the Club/Association  
Au club/association  
An Klub/Verband

☐ Other address:  
Autre adresse:  
Andere Adresse:

Team

Equipe  
Mannschaft

Player's number  
N° du joueur  
Nr. des Spielers

Name of the accompanying official  
Nom de l'officiel accompagnant le joueur  
Name des offiziellen Begleiters

### Urine Test / Contrôle d'urine / Urinkontrolle

In our presence and under our strict control,  
the player gave a urine sample at  
\_\_\_\_\_ hours \_\_\_\_\_ minutes.

En notre présence et sous notre contrôle,  
le joueur a fourni un échantillon d'urine à  
\_\_\_\_\_ heures \_\_\_\_\_ minutes.

In unserer Gegenwart und unter unserer strikten  
Kontrolle hat der Spieler um \_\_\_\_\_ Uhr \_\_\_\_\_ Minuten  
eine Urinprobe abgegeben.

pH

The urine sample has been decanted into two  
separate bottles labelled "A" and "B", bearing the  
code numbers below. These bottles have been  
sealed for transport in accordance with the  
regulations.

L'échantillon d'urine a été versé dans deux  
flacons «A» et «B» portant les codes  
ci-dessous. Ces flacons ont été scellés  
pour le transport, conformément au règlement.

S/G

Die Urinprobe wurde in zwei kodierte (siehe unten)  
Flaschen mit der Beschriftung «A» und «B» gefüllt.  
Diese Flaschen wurden dem Règlement entsprechend  
für den Transport versiegelt.

UEFA

A

☐ The player refused to give a urine sample

☐ The player poured the urine into bottles "A" and "B"  
himself

☐ The player asked and authorized the Doping Control  
Officer to pour the urine into bottles "A" and "B"

☐ Le joueur a refusé de fournir un échantillon d'urine.

☐ Le joueur a versé lui-même l'urine dans les flacons  
A et B

☐ Le joueur a demandé au contrôleur antidopage de  
verser l'urine dans les flacons A et B et lui en a  
donné l'autorisation

UEFA

B

☐ Der Spieler hat die Abgabe einer Urinprobe verweigert.

☐ Der Spieler hat den Urin selbst in die Flaschen  
A und B gefüllt

☐ Der Spieler hat den Dopingkontrollleur gebeten und  
ermächtigt, den Urin in die Flaschen A und B zu füllen

The whole procedure took place in the presence  
of the UEFA Doping Control Officer and the  
official accompanying the player.

L'ensemble de la procédure s'est déroulée en  
présence du contrôleur antidopage de l'UEFA  
et de l'officiel accompagnant le joueur.

Alle Vorgänge wurden in Anwesenheit des  
UEFA-Dopingkontrollleuers und des offiziellen  
Begleiters des Spielers durchgeführt.

#### Resolution of disputes

I agree that any dispute not resolved after exhaustion  
of the legal remedies established by UEFA shall be  
submitted exclusively to the Court of Arbitration for  
Sport (CAS) for final and binding arbitration. I take note  
that I must submit such a dispute to the CAS within  
10 days of the notification of the decision, which is  
challenged. I also take note that proceedings before  
CAS shall take place in accordance with the Code of  
Sports-related Arbitration of CAS.  
The CAS shall rule on its jurisdiction and has the  
exclusive power to order provisional and conservatory  
measures. The decisions of CAS shall be final.

#### Règlement des litiges

J'accepte que tout litige non résolu après épuisement  
des voies de droits établies par l'UEFA sera soumis  
exclusivement au Tribunal Arbitral du Sport (T.A.S.) et  
tranché de manière définitive et obligatoire. Je prends  
note que je dois soumettre un tel litige dans un délai  
de 10 jours après notification de la décision contestée.  
Je prends également note que la procédure suit les  
dispositions du Code de l'arbitrage en matière de sport  
du T.A.S.  
Le T.A.S. statue sur sa compétence et a le pouvoir  
exclusif d'ordonner des mesures provisionnelles et  
conservatoires. Les décisions du T.A.S. sont  
définitives.

#### Streitigkeiten

Ich akzeptiere, dass alle Streitigkeiten im Zusammenhang  
mit Dopingangelegenheiten nach Ausschöpfung der von  
der UEFA vorgesehenen Rechtsmittel ausschließlich und  
endgültig durch das Schiedsgericht des Sports «TAS»  
entschieden werden. Ich nehme davon Kenntnis, dass  
eine allfällige Klage innert 10 Tagen nach Eröffnung des  
anzurechtend Entscheides beim «TAS» einzureichen  
ist. Ich nehme ebenfalls davon Kenntnis, dass sich das  
Verfahren nach der Schiedsordnung für Streitigkeiten im  
Bereich des Sports des «TAS» richtet.  
Das «TAS» beurteilt seine Zuständigkeit selber und kann  
vorläufige oder sichernde Massnahmen anordnen. Der  
Schiedsspruch des «TAS» ist endgültig.

Remarks  
Remarques  
Bemerkungen

I certify that, subject to my above comments in the  
«Remarks» section, the testing was collected in  
accordance with UEFA regulations and procedures  
and that no subsequent complaint is possible

Je certifie que, sous réserve des commentaires  
ci-dessus figurant dans la rubrique «Remarques»,  
le prélèvement s'est déroulé en conformité avec le  
règlement et les procédures de l'UEFA et que toute  
plainte ultérieure est exclue.

Ich bestätige, dass die Probe unter Vorbehalt meiner  
Kommentare in der Rubrik „Bemerkungen“ in Übereinstimmung  
mit dem Règlement und den Verfahren  
der UEFA entnommen wurde und dass keine nach-  
träglichen Beschwerden möglich sind.

Player's signature  
Signature du joueur  
Unterschrift des Spielers

Accompanying official's signature  
Signature de l'officiel accompagnant le joueur  
Unterschrift des offiziellen Begleiters des Spielers

Signature of the UEFA Doping Control Officer  
Signature du contrôleur antidopage de l'UEFA  
Unterschrift des UEFA-Dopingkontrollleuers

D5

Partial Sample form (D6)



Partial Sample  
Echantillon partiel  
Teilprobe



Union des associations européennes de football  
Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31

I, the undersigned player, confirm that the quantity of urine indicated below provided by me has been poured into the 'A' bottle. This bottle has been sealed with the interim sealing device before replacing the cap on the bottle. The 'A' bottle has been placed back in the polystyrene foam packaging, which also contains bottle 'B', and sealed with the security tape.

Le joueur soussigné confirme que le volume d'urine ci-dessous qu'il a fourni a été versé dans le flacon «A». Ce flacon a été scellé au moyen du mécanisme de scellage provisoire avant de replacer le bouchon. Le flacon «A» a été replacé dans l'emballage en polystyrène, qui contient également le flacon «B», et scellé avec la bande adhésive de sécurité.

Der unterzeichnende Spieler bestätigt, dass die folgende von ihm abgegebene Urinmenge in die Flasche «A» abgefüllt wurde. Diese Flasche wurde mit dem Zwischenversiegelungszapfen versiegelt und der Deckel auf die Flasche gestülpt. Die Flasche «A» wurde darauf in die Styroporschachtel gelegt, die auch die Flasche «B» enthält, und mit dem Sicherheitsklebeband verschlossen.

Quantity of urine / Volume d'urine / Urinmenge (ml)	Security tape number Code de la bande de sécurité Kodenummer des Sicherheitsklebebandes
Full name of the player / Nom et prénom du joueur / Name und Vorname des Spielers	
Player's signature / Signature du joueur / Unterschrift des Spielers	
Signature of the UEFA Doping Control Officer / Signature du contrôleur antidopage de l'UEFA / Unterschrift des UEFA-Dopingkontrollleurs	

This part of the form must be detached and retained by the player until he is able to provide the required quantity of urine.  
Ce talon doit être détaché et conservé par le joueur jusqu'à ce qu'il soit en mesure de fournir le volume d'urine requis.  
Dieser Abschnitt muss abgetrennt und vom Spieler so lange aufbewahrt werden, bis er in der Lage ist, die erforderliche Urinmenge abzugeben.

Security tape number Code de la bande de sécurité Kodenummer des Sicherheitsklebebandes	Player's signature Signature du joueur Unterschrift Spieler

Chain of Custody and Confirmation of Receipt by Laboratory form (D7)



Chain of Custody and Confirmation of Receipt by Laboratory  
Acheminement des échantillons et accusé de réception du laboratoire  
Beleg über die Weitergabe der Proben und Empfangsbestätigung des Labors

Union des associations européennes de football  
Route de Genève 46 | CH-1260 Nyon 2 | Switzerland | Tel. +41 848 00 27 27 | Fax +41 22 990 31 31

- ☐ In competition  
En compétition  
in Wettbewerb
- ☐ Out-of-competition  
Hors compétition  
Ausserhalb von Wettbewerben
- ☐ Female  
Femme  
Frau
- ☐ Male  
Homme  
Mann
- ☐ EPO
- ☐



Sample numbers/Numéros des échantillons/Nummern der Proben

UEFA	A	UEFA	B
UEFA	A	UEFA	B
UEFA	A	UEFA	B
UEFA	A	UEFA	B
UEFA	A	UEFA	B
UEFA	A	UEFA	B
UEFA	A	UEFA	B
UEFA	A	UEFA	B
UEFA	A	UEFA	B
UEFA	A	UEFA	B

After collection, the above samples numbers were entrusted to the following persons:  
Après avoir été prélevés les numéros d'échantillons ci-dessus ont été confiés aux personnes suivantes:  
Die oben aufgeführten Proben wurden an folgende Personen weitergegeben:

Number of samples Nombre d'échantillons Anzahl der Proben	Name of person receiving samples Nom de la personne qui reçoit les échantillons Name der Person, die die Proben erhält	Reason (e.g. transport to the laboratory, etc.) Motif (ex. transport au laboratoire, etc.) Begründung (z.B. Transport zum Labor usw.)	Signature Signature Unterschrift	Place/Date Lieu/Date Ort/Datum

The above samples numbers were entrusted to the following laboratory:  
Les numéros d'échantillons ci-dessus ont été confiés au laboratoire suivant:  
Die oben aufgeführten Proben wurden an das folgende Labor weitergeleitet:

Name of Laboratory Nom du laboratoire Name des Labors	
Name of person receiving samples Nom de la personne qui reçoit les échantillons Name der Person, die die Proben entgegennimmt	
Signature Signature Unterschrift	
Place/Date Lieu/Date Ort/Datum	

## APPENDIX E: Definitions

**Adverse Analytical Finding:** A report from a laboratory or other approved Testing entity that identifies in a *Specimen/Sample* the presence of a *Prohibited Substance* or its *Metabolites* or *Markers* (including elevated quantities of endogenous substances) or evidence of the *Use of a Prohibited Method*.

**Anti-Doping Organisation:** An organisation that is responsible for adopting rules for initiating, implementing or enforcing any part of the *Doping Control* procedure. This includes, for example, FIFA and the national anti-doping organisation, which may be either the national Olympic committee or another designated body.

**Attempt:** Purposely engaging in conduct that constitutes a substantial step in a course of conduct planned to culminate in the commission of an anti-doping rule violation. However, there shall be no anti-doping rule violation based solely on an *Attempt* to commit a violation if the *Person* renounces the attempt prior to it being discovered by a third party not involved in the *Attempt*.

**Chaperone:** A person appointed by UEFA who notifies the player assigned to him from among those selected for a doping control and accompanies the player from the time he is notified until the doping control is completed. If UEFA does not appoint a chaperone, the team has to appoint a representative to notify the players of his team and accompany them to the doping control station.

**Code:** The World Anti-Doping Code.

**Doping Control:** The procedure including test distribution planning, *Sample* collection and handling, laboratory analysis, results management, hearings and appeals.

**Doping Control Liaison Officer:** A person appointed by the home team who is at the disposal of the DCO. His main task is to ensure that the doping control station and all necessary materials and equipment are available and ready for the purposes of the doping control, as described in Appendices A and B. He must also organise return transport to the hotel for the DCO.

**Doping Control Officer Assistant:** A person appointed by UEFA who assists the DCO in his work from the time of the latter's arrival at the stadium until completion of the doping control. His main tasks are to register all persons entering the doping control station on the Doping Control Station Register form (D4) and to supervise the working area of the doping control station.

**Doping Control Officer (DCO):** A physician (male or female) who is part of the DCO Panel and is appointed by the UEFA Anti-Doping Unit to conduct a doping control. He/she shall be responsible for the entire doping control procedure, including the draw, the collection of samples and the transport of samples to the WADA-accredited laboratory.



*International Standard or WADA International Standard*: A standard adopted by WADA in support of the *Code*. Compliance with the *International Standard* (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures were performed properly.

*Marker*: A compound, group of compounds or biological parameters that indicates the *Use of a Prohibited Substance or Prohibited Method*.

*Metabolite*: Any substance produced by a biotransformation process.

*Minor*: A natural *Person* who has not reached the age of majority as established by the applicable laws of his or her country of residence.

*No Fault or Negligence*: If the *player* establishes that he or she did not know or suspect, and could not reasonably have known or suspected, even with the exercise of utmost caution, that he or she had *Used* or been administered the *Prohibited Substance or Prohibited Method*.

*Player*: For the purposes of *Doping Controls*, any *Person* who participates in a UEFA competition.

*Player Support Personnel*: Any coach, trainer, manager, agent, team staff, official, medical or paramedical personnel working with or treating *Players* participating in or preparing for sports competition.

*Person*: A natural person or a juristic person.

*Possession*: The actual, physical possession, or the constructive possession (which shall be found only if the person has exclusive control over the *Prohibited Substance/Method* or the premises in which a *Prohibited Substance/Method* exists); provided, that if the person does not have exclusive control over the *Prohibited Substance/Method* or the premises in which a *Prohibited Substance/Method* exists, constructive possession shall only be found if the person knew about the presence of the *Prohibited Substance/Method* and intended to exercise control over it. However, there shall be no anti-doping rule violation based solely on possession if, prior to receiving notification of any kind that the *Person* has committed an anti-doping rule violation, the *Person* has taken concrete action demonstrating that the *Person* no longer intends to have *Possession* and has renounced the *Person's* previous *Possession*.

*Prohibited List*: The WADA list identifying *Prohibited Substances* and *Prohibited Methods*.

*Prohibited Method*: Any method so described on the *Prohibited List*.

*Prohibited Substance*: Any substance so described on the *Prohibited List*.

Sample/Specimen: Any biological material collected for the purposes of *Doping Control*.

Tampering: Altering for an improper purpose or in an improper way; bringing improper influence to bear; interfering improperly to alter results or prevent normal procedures from occurring.

Target Testing: Selection of *Players* for Testing where specific *Players* or groups of *Players* are selected on a non-random basis for *Testing* at a specified time.

Team: All players participating in a match or a club or a national team.

Team representative: A person appointed by his team as its representative at the half-time draw, at the opening of the envelopes and when the players from his team are tested.

Trafficking: To sell, give, administer, transport, send, deliver or distribute a *Prohibited Substance* or *Prohibited Method* to a *Player* either directly or through one or more third parties, but excluding the sale or distribution (by medical personnel or by *Persons* other than a *Player Support Personnel*) of a *Prohibited Substance* for genuine and legal therapeutic purposes.

Use: The application, ingestion, injection or consumption by any means whatsoever of any *Prohibited Substance* or *Prohibited Method*.

WADA: The World Anti-Doping Agency.

Whereabouts information: information regarding date, time and place (full address) of training sessions, matches and any other activities of a team or player.

## **Appendix F: Whereabouts information for out-of-competition testing**

### **Testing pool**

1. The UEFA Anti-Doping Panel shall identify a UEFA out-of-competition registered testing pool of those teams and/or players which/who are required to provide up-to-date whereabouts information to UEFA.
2. The Anti-Doping Panel shall define the criteria for teams and/or players to be included in the registered testing pool and may also include players individually. The Anti-Doping Panel may revise the registered testing pool from time to time as appropriate.
3. Teams and/or players will remain in the registered testing pool and continue to be required to provide up-to-date whereabouts information to UEFA until they have been informed by the Anti-Doping Panel that they have been removed from the registered testing pool.

Players who are under a period of suspension will remain in the registered testing pool and continue to be required to provide whereabouts information.

Players who are transferred to another team or have given notice of retirement from football to their team may be required to provide whereabouts information and must remain available for unannounced out-of-competition testing during a period of six months.

*Comment: Notice of retirement is effective only when the player has returned his licence to his national association for that purpose.*

### **Whereabouts information requirements**

4. The Anti-Doping Panel shall notify teams and/or players in the registered testing pool in writing that they have been included in the pool and that they must provide accurate whereabouts information in accordance with the present appendix and with any further instructions that the Anti-Doping Panel may deem appropriate.

The notification shall set the deadline for the submission of whereabouts information by the teams and/or players.

When a team is part of the registered testing pool, it shall be responsible for collecting and forwarding to the Anti-Doping Panel the whereabouts information of all its players registered to participate in the UEFA competition.

However, the ultimate responsibility for providing whereabouts information rests with each player and he/she must make sure to keep his/her team informed when he/she is not participating or involved in team activities.

5. All teams and/or players in the registered testing pool shall send reports to the Anti-Doping Panel on forms provided by UEFA which specify on a daily basis the locations where the teams and/or players will be residing and the times when they will be training and competing.
6. Should a team and/or player's plans change from those originally submitted on the whereabouts information forms, the team and/or player shall immediately send updates of all information required on the form so that it is current at all times.
7. The team and/or player shall send whereabouts information and updates by fax to the Anti-Doping Panel using the confidential number +41 22 990 31 31. The team and/or player may also provide whereabouts information and updates by electronic means to [anti-doping@uefa.ch](mailto:anti-doping@uefa.ch).

### **Failure to comply**

8. For each attempt to locate the team and/or player for testing, the Doping Control Officer will visit all locations during the times specified by the team and/or player for that date and will stay one hour at each location (or until the scheduled departure time from that location previously specified by the team and/or player, if earlier).
9. Should the team fail to be located for testing on the basis of the most up-to-date whereabouts information it has supplied, or fail to provide complete, adequate or accurate whereabouts information, or fail to provide whereabouts information in time, the Anti-Doping Panel will notify the team in writing of any such failure.  
Any such failure committed by the team without sufficient reason will be reported to the Control & Disciplinary Body.
10. Should a player fail to be located for testing on the basis of the most up-to-date information received from the team and/or player, the Anti-Doping Panel will notify the team and player in writing of any such failure.  
Any such failure committed by a player without sufficient reason will be reported to the Control and Disciplinary Body.

A total of three instances of failure to provide accurate whereabouts information and/or a missed test in a rolling period of 24 months constitutes an anti-doping rule violation by the player concerned under Article 2 of the Anti-Doping Regulations.

11. A team and/or player's failure to provide accurate whereabouts information and/or missed tests in accordance with the present appendix may be combined with failures to provide accurate whereabouts information and/or missed tests recorded by other anti-doping organisations, provided (i) the anti-doping organisation had authority under the Code, (ii) the Anti-Doping Panel was informed in time and (iii) the facts recorded by the anti-doping

organisation constitute, to the satisfaction of the Anti-Doping Panel, a failure to provide accurate whereabouts information or a missed test in accordance with the present appendix.

### **Coordination with anti-doping organisations**

12. UEFA may also collect whereabouts information from the national associations, WADA and other anti-doping organisations.
13. UEFA may make the list of teams and/or players in the registered testing pool available to WADA and other anti-doping organisations.
14. UEFA may submit all whereabouts information to WADA, which may make such information accessible to other anti-doping organisations having authority to test the team and/or player as defined in the Code.
15. UEFA may supply whereabouts information to other anti-doping organisations having authority to test the team and/or player as defined in the Code.

### **Confidentiality**

16. UEFA shall maintain whereabouts information in strict confidence at all times and shall use it exclusively for the purposes of planning, coordinating or conducting tests. UEFA shall destroy whereabouts information when it is no longer relevant for these purposes.
17. Under the Code, WADA and all anti-doping organisations that have accepted the Code are bound by the same obligations concerning the confidentiality of whereabouts information.

However, UEFA shall not be liable for any use that WADA or any anti-doping organisation makes of whereabouts information, even if the information was provided by UEFA. Teams and/or players shall have no claim against UEFA in this respect.

## INDEX

Analysis of samples .....	11
Anti-doping rule violations .....	1
Blood sampling .....	13
Burdens and standards of proof .....	2
Chain of custody and confirmation of receipt by laboratory form (D7) .....	33
Declaration of medication form (D3) .....	28
Definition of doping .....	1
Definitions .....	34
Disciplinary procedure in the event of anti-doping rule violations .....	15
Doping Control Draw form (D1) .....	25
Doping control draw procedure for urine samples .....	5
Doping control form (D5) .....	31
Doping control procedure for urine samples .....	9
Doping control station .....	9
Doping Control Station Register form (D4) .....	29
Doping Control Station Register form (D400CT) .....	30
Draw procedure for out-of- competition controls .....	7
Further provisions .....	15
Instructions to organisers of UEFA matches .....	17
List of WADA-accredited laboratories in Europe .....	20
Methods of establishing facts and presumptions .....	2
Obligations of national associations, clubs and players .....	5
Organisation .....	4
Partial sample form (D6) .....	32
Plan of Doping Control Station .....	19
Procedure if sample A produces an adverse analytical finding .....	11
Procedure if the analysis of the “B” sample proves positive .....	13
Procedure if the stipulated urine volume of 75 ml is not obtained .....	10
Prohibited substances and methods .....	3
Proof of doping .....	2
Right to request an analysis of sample B .....	12
Summons for doping control form (D2) .....	26
Summons for Out-of-competition Doping Control form (D200CT) .....	27
Suspicion of doping .....	8
Therapeutic Use Exemption (TUE) .....	3
Whereabouts information requirements .....	37



UEFA  
Route de Genève 46  
CH-1260 Nyon 2  
Switzerland  
Telephone +41 848 00 27 27  
Telefax +41 848 01 27 27  
uefa.com

Union des associations  
européennes de football

